Microfluidic Market, By Product Type (Microfluidic-Based Devices and Microfluidic Components), By Material (Polymer, Glass, Silicon, Metal, Ceramics), By Application (Point of care testing, Clinical Diagnostics, Drug Delivery, Analytical Testing, Genomics, Proteomics, Cell based Analysis, Others), By End User (Hospitals & Diagnostic Centers, Academic & Research Institute, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Feb 2025

Code : CMI1086

Pages :161

Formats :

Excel and PDF

Industry : Medical Devices

Microfluidic Market Size and Trends

Global microfluidic market is estimated to be valued at USD 38.13 Bn in 2025 and is expected to reach USD 102.74 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 15% from 2025 to 2032.

Microfluidic Market Key Factors

To learn more about this report, Request sample copy

Rising demand for point-of-care testing and organ-on-chip technology in drug discovery can drive the market growth. Furthermore, increasing investments in research activities associated with microfluidics by public and private organizations can also drive the market growth. Various industries like in-vitro diagnostics, pharmaceutical and biotechnology are increasingly adopting microfluidic products and systems for improved precision, speaed and efficiency. The development of innovative application-specific microfluidic systems for fields including genomics and proteomics can offer new opportunities for market players in the near future.

Market Driver – Growing Demand for Point-of-Care Testing

Global microfluidic market growth is driven by increasing demand for point-of-care testing. Point-of-care testing allows diagnostic tests to be carried out nearer to the patient with quick results. This has been a boon especially for patients in remote locations who would otherwise have to travel long distances to a laboratory for regular testing. Microfluidic technology enables the miniaturization of laboratory functions on a single microchip, allowing complex chemical and biological diagnostic tests to be performed outside a laboratory setting. For example, microfluidic chips can now perform tests like glucose monitoring, immunoassays, DNA analysis from small and easily accessible samples like drops of blood via a fingerpick. This not only saves travel time and costs for patients but also provides real-time monitoring capabilities. Due to rising need for timely test results to make critical treatment decisions, there has been huge adoption of microfluidics for developing portable and handheld diagnostic tools near patients. Its ability to integrate multiple assay steps onto a single device while requiring minute sample volumes can attract researchers developing technologies like mobile health testing. For instance, according to the data published by Cancer Australia in 2023, 162,163 new cancer cases were diagnosed in Australia in 2022. This significant prevalence of cancer cases can boost demand for point-of-care diagnostics, thus, driving the market growth.